Guide · 7 min

Tirzepatide: the buyer's guide for 2026.

Last updated May 2026

Tirzepatideis on the pharmacy shelf as Mounjaro and Zepbound. It’s also on the research-peptide market for 30–50% less, with the same active ingredient. This is the actual buyer’s guide — pricing, vial choices, vendor evaluation, titration math.

If you want the mechanism explainer, the GLP-1 family post covers that. If you want to know whether tirzepatide beats semaglutide, the head-to-head comparison is the place. This post is about buying it.

Pharmacy vs research-peptide

Pharmacy tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is the brand-name route. Pros: prescription-backed, insurance may cover it, pre-filled pens (no reconstitution math). Cons: $1,000+ per month cash price without a coupon or insurance, supply has been intermittent, requires an active prescription.

Research-peptide tirzepatide is the underground market. Pros: typically a fraction of pharmacy cash price, no prescription needed, COA-tested vials from reputable vendors. Cons: you’re injecting based on label-stated concentration (trust the vendor’s testing), no insurance coverage, you do the reconstitution math yourself.

Both routes deliver tirzepatide. The mechanism is identical because the molecule is identical.

Vial sizes you’ll see

Pricing per mg drops as vial size grows. The 20 mg vial is usually the sweet spot — enough supply for a 2-week dosing cycle, doesn’t sit too long after reconstitution.

The reconstitution math

NovaPeptide sells a 20 mg vial designed for 2 mL of bacteriostatic water → 10 mg/mL working concentration. Standard math from there:

For other vial sizes or water amounts, use the tirzepatide reconstitution calculator.

The titration schedule

The FDA-approved titration for both Mounjaro and Zepbound mirrors what most research-peptide users follow:

Many users report finding their working dose between 7.5 and 12.5 mg/week. Going to 15 mg gives diminishing returns relative to side effects for non-clinical populations.

Managing side effects

Nausea is the dominant complaint. It usually peaks 24–48 hours post-injection and resolves by day 4–5. Strategies that actually help:

BPC-157 helps some users with the GI side effects through its gut-healing mechanism. Daily 250–500 mcg subq.

Evaluating a vendor

For research-peptide tirzepatide specifically, the things that matter:

  1. Third-party COA on every batch — not “on request” or “available.” Every batch.
  2. Purity ≥99% measured by HPLC. Lower than 99% means impurity bands that will produce inconsistent dosing.
  3. Net peptide content stated separately from total mass — peptide vials include some salt/excipient by mass.
  4. Endotoxin and sterility testing — non-negotiable for injectable products.
  5. Discreet packaging and US-based shipping — if you’re paying for product, you should get product.

NovaPeptide is our top-ranked vendor for exactly these reasons. The COA is published, purity is above 99%, the testing is genuinely third-party, customer service responds. Use the BIOHACKMAXX code at checkout.

Maintenance after weight goal

Tirzepatide isn’t a “lose the weight, stop the drug, keep the result” tool. Stopping abruptly causes severe appetite rebound and most users regain a significant portion of the lost weight within months.

The maintenance protocol: stay on the lowest dose that suppresses appetite. For most that’s 5–7.5 mg/week indefinitely. Some users can step down to 2.5 mg/week if their relationship with food has fundamentally shifted during the weight-loss phase. Plan for ongoing use.

Bottom line

Tirzepatide is the best fat-loss tool currently in market. Research-peptide sourcing through a reputable vendor is a fraction of the pharmacy cash price with no meaningful difference in the active compound. The titration schedule is real — follow it. The maintenance phase is real — plan for it.

For the math on your specific vial, the tirzepatide calculator handles every dose tier. For the comparison versus semaglutide and retatrutide, the head-to-head lays out the trade-offs.